Copeland Capital Management LLC Purchases Shares of 1,436 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Copeland Capital Management LLC opened a new position in Regeneron by acquiring 1,436 shares in Q4, worth about $1.11 million, joining other institutional holders in a stock that is 83.31% institutionally owned.
• Regeneron beat Q4 expectations with $11.44 EPS and $3.88 billion in revenue, raised its quarterly dividend to $0.94 (annualized $3.76), and carries an analyst consensus of "Moderate Buy" with an average target near $825.
• Major corporate developments include FDA approval of the gene therapy Otarmeni (which Regeneron will provide free to eligible U.S. patients) and tariff relief, though a drug‑pricing deal involving most‑favored‑nation pricing could pressure future margins.

Copeland Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,436 shares of the biopharmaceutical company's stock, valued at approximately $1,108,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Lebenthal Global Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $495,000. Cora Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $204,000. WPG Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 25 shares in the last quarter. Atwood & Palmer Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.9% during the 4th quarter. Atwood & Palmer Inc. now owns 41,817 shares of the biopharmaceutical company's stock valued at $32,277,000 after purchasing an additional 386 shares during the last quarter. Finally, Chicago Partners Investment Group LLC lifted its holdings in Regeneron Pharmaceuticals by 42.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 1,345 shares of the biopharmaceutical company's stock valued at $1,014,000 after purchasing an additional 400 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ REGN opened at $751.57 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a market cap of $79.46 billion, a PE ratio of 18.08, a P/E/G ratio of 1.71 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $762.84 and a two-hundred day moving average of $731.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals's revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.07 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's dividend payout ratio is 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director owned 17,803 shares of the company's stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 3,774 shares of company stock worth $2,942,738. Insiders own 7.02% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, April 11th. Piper Sandler began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued an "overweight" rating and a $875.00 target price on the stock. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an "equal weight" rating in a report on Friday, April 10th. Finally, Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an "equal weight" rating in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $825.35.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.